CFO
CRNX icon

Callan Family Office’s Crinetics Pharmaceuticals CRNX Stock Holding History

Callan Family Office’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,002
Closed -$233K – 1146
2025
Q4 		$233K Buy
+5,002
New +$223K 0.01% 1006

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Callan Family Office's CRNX Position: Q1 2026 in Review

Callan Family Office sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,002 shares — an estimated $233K sold.

Callan Family Office first reported a position in CRNX in Q4 2025 and held it in 1 quarter. The position peaked at $233K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Callan Family Office reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Callan Family Office sold 5,002 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $233K.
  • Callan Family Office first reported a position in Crinetics Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Callan Family Office's Crinetics Pharmaceuticals position peaked at $233K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.